Decoding Clinical Biomarker Space of COVID-19: Exploring Matrix Factorization-based Feature Selection Methods

Farshad Saberi-Movahed; Mahyar Mohammadifard; Adel Mehrpooya; Mohammad Rezaei-Ravari; Kamal Berahmand; Mehrdad Rostami; Saeed Karami; Mohammad Najafzadeh; Davood Hajinezhad; Mina Jamshidi; Farshid Abedi; Mahtab Mohammadifard; Elnaz Farbod; Farinaz Safavi; Mohammadreza Dorvash; Shahrzad Vahedi; Mahdi Eftekhari; Farid Saberi-Movahed; Iman Tavassoly

doi:10.1101/2021.07.07.21259699

Abstract

One of the most critical challenges in managing complex diseases like COVID-19 is to establish an intelligent triage system that can optimize the clinical decision-making at the time of a global pandemic. The clinical presentation and patients’ characteristics are usually utilized to identify those patients who need more critical care. However, the clinical evidence shows an unmet need to determine more accurate and optimal clinical biomarkers to triage patients under a condition like the COVID-19 crisis. Here we have presented a machine learning approach to find a group of clinical indicators from the blood tests of a set of COVID-19 patients that are predictive of poor prognosis and morbidity. Our approach consists of two interconnected schemes: Feature Selection and Prognosis Classification. The former is based on different Matrix Factorization (MF)-based methods, and the latter is performed using Random Forest algorithm. Our model reveals that Arterial Blood Gas (ABG) O₂ Saturation and C-Reactive Protein (CRP) are the most important clinical biomarkers determining the poor prognosis in these patients. Our approach paves the path of building quantitative and optimized clinical management systems for COVID-19 and similar diseases.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Acknowledgments I.T. contributed to this paper at the Cellular Energetics Program of the Kavli Institute for Theoretical Physics, supported in part by the National Science Foundation Grant NSF PHY-1748958, NIH Grant R25GM067110, and the Gordon and Betty Moore Founda- tion Grant 2919.02. This work was partly supported by the Intramural Research Pro- gram of the National Institute of Neurological Disorder and Stroke/ National Institutes of Health (Grant NS003031) (to F.S.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board (IRB) of Birjand University of Medical Sciences in Iran approved this study. Anonymised clinical data of all patients with COVID-19 who had been admitted in clinical centers of Birjand University of Medical Sciences during the mentioned time were used according to the Institutional Review Board (IRB) of Birjand University of Medical Sciences permission.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Participants of this study did not agree for their data to be shared publicly, so supporting data is not available.

Abbreviations

(ALT): Alanine Aminotransferase
(ABG): Arterial Blood Gas
(AI): Artificial Intelligence
(AST): Aspartate Aminotransferase
(CNS): Central Nervous System
(ACC): Classification/Clustering Accuracy
(CBC): Complete Blood Count
(CNMF): Convex NMF
(COVID-19): Coronavirus Disease 2019
(CV): Cross-Validation
(CRP): C-Reactive Protein
(DLBCL): Diffuse large B-cell lymphoma
(FN): False Negative
(False Positive): False Positive
(FS): Feature Selection
(HSIC): Hilbert Schmidt Independence Criterion
(INR): International Normalized Ratio
(Isomap): Isometric Feature Mapping
(LDA): Linear Discriminant Analysis
(LPP): Locality Preserving Projection
(LLE): Locally Linear Embedding
(ML): Machine Learning
(MF): Matrix Factorization
(MFFS): Matrix Factorization Feature Selection
(MPMR): Maximum Projection and Minimum Redundancy
(MCFS): Multi-Cluster Feature Selection
(NPV): Negative Predictive Value
(NPE): Neighborhood Preserving Embedding
(NMF): Non-Negative Matrix Factorization
(NMI): Normalized Mutual Information
(ONMF): Orthogonal NMF
(PMH): Past Medical History
(PTT): Partial Thromboplastin Time
(PCR): Polymerase Chain Reaction
(PPV): Positive Predictive Value
(PCA): Principal Components Analysis
(PMF): Probabilistic Matrix Factorization
(RMFFS): Regularized Matrix Factorization Feature Selection
(SNMF): Semi NMF
(SVD): Singular Value Decomposition
(SRBCT): Small Round Blue Cell Tumors
SLSDR): Sparse and Low-redundant Subspace learning-based Dual-graph Regularized Robust
(SGFS): Subspace Learning-Based Graph Regularized Feature Selection
(TN): True Negative
(TNR): True Negative Rate
(TP): True Positive
(TPR): True Positive Rate
(WBC): White Blood Cells

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.